Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
From bluebird bio, Inc.
Via Business Wire
bluebird bio stock trading halted today June 9th and tomorrow June 10th
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US
From bluebird bio, Inc.
Via Business Wire
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor
From bluebird bio, Inc.
Via Business Wire
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM
From bluebird bio, Inc.
Via Business Wire
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc
Via Business Wire
bluebird bio Completes Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
bluebird bio Provides Update on Upcoming Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
2seventy bio Announces Upcoming Investor Events
From bluebird bio
Via Business Wire
bluebird bio Secures $75 Million in Private Placement Equity Financing
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
From bluebird bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback